The Japanese pharmaceutical market is seeing more and more foreign entrants. There are two main ways to enter the market: establishing a direct presence in Japan by setting up your own branch office or a 100% owned subsidiary, or, alternatively, forming marketing alliances including licensing agreements. There are usually many factors that together will determine the most suitable entry strategy for a company. Although the choices for market entry may be similar to those for other countries, the implications of each choice can be quite different in Japan and it is therefore important to fully understand the legal aspects of each entry option. )
The webinar is targeted at EU companies seeking to enter the Japanese nanomedicine/pharmaceutical market.
Registrations are open until the 06/06/2014 included.
What will you learn in this webinar?
In 40 minutes, from the comfort of your desk, you will discover:
Speaker: Maths Lundin, SJC KK
Organiser: EU-Japan Centre for Industrial Cooperation - Brussels Office
The EU-Japan Centre currently produces 5 newsletters :